Who
Robert Weinstein
Director
Company insider
Files Form 4 as: Director, Xwell; Chief Financial Officer, Tao Synergies; Director, PharmaCyte Biotech; Officer, Neurotrope; Chief Financial Officer, CDSS Wind Down; Chief Financial Officer, Xcorporeal.
In numbers
- Trades disclosed
- 67
- Buys
- 3
- Sells
- 4
- Bought
- $43K
- Sold
- $240K
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 2 Apr 2008
- Last trade
- 25 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Aug 2026filed 2 Sep 2026 | XWEL XwellConsumer Services | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 25 Aug 2026filed 2 Sep 2026 | XWEL XwellConsumer Services | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | TAOX Tao Synergiesoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | TAOX Tao Synergiesoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 31 Mar 2026filed 17 Jul 2026 | PMCB PharmaCyte Biotechoption or derivative · Biotechnology | SEC FORM 4 Code J | —0 | filing |
| 31 Mar 2026filed 17 Jul 2026 | PMCB PharmaCyte Biotechoption or derivative · Biotechnology | SEC FORM 4 Code J | —0 | filing |
| 31 Mar 2026filed 2 Apr 2026 | PMCB PharmaCyte Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,170 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | PMCB PharmaCyte Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,170 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | XWEL XwellConsumer Services | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | XWEL XwellConsumer Services | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | PMCB PharmaCyte BiotechBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | PMCB PharmaCyte BiotechBiotechnology | SEC FORM 4 Code F | $34K33,750 at $1.02 | filing |
| 17 Oct 2025filed 17 Oct 2025 | TAOX Tao SynergiesConsumer & Specialty Finance | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 17 Oct 2025filed 17 Oct 2025 | TAOX Tao SynergiesConsumer & Specialty Finance | SEC FORM 4 Code F | $29K4,000 at $7.23 | filing |
| 6 Aug 2025filed 17 Oct 2025 | TAOX Tao Synergiesoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | TAOX Tao SynergiesConsumer & Specialty Finance | SEC FORM 4 Code A | —15,410 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | TAOX Tao SynergiesConsumer & Specialty Finance | SEC FORM 4 Code F | $48K6,164 at $7.85 | filing |
| 2 Jun 2025filed 3 Jun 2025 | XWEL Xwelloption or derivative · Consumer Services | SEC FORM 4 Code A | —117,886 at $0.00 | filing |
| 2 Jun 2025filed 3 Jun 2025 | XWEL XwellConsumer Services | SEC FORM 4 Code A | —107,407 | filing |
| 25 Apr 2025filed 12 Dec 2025 | PMCB PharmaCyte Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —63,233 at $0.00 | filing |
News
Contrasting American Public Education (NASDAQ:APEI) and XWELL (NASDAQ:XWEL)XWEL · themarketsdaily.com · 18 Oct 2026Head-To-Head Contrast: Synaptogenix (NASDAQ:TAOX) and Otsuka (OTCMKTS:OTSKY)TAOX · tickerreport.com · 14 Oct 2026Synaptogenix (NASDAQ:TAOX) Stock Rating Lowered by Wall Street ZenTAOX · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Robert Weinstein; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.